Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InSilico Medicine Cayman TopCo ( (HK:3696) ) just unveiled an update.
InSilico Medicine Cayman TopCo announced that the stabilization period for its Hong Kong initial public offering has ended, with Morgan Stanley Asia Limited, acting as stabilizing manager, having made over-allocations of 14,203,500 shares in the international tranche, equal to about 15% of the total offer size. The over-allotment option was fully exercised at HK$24.05 per share to return the borrowed shares to chairman and CEO Aleksandrs Zavoronkovs, and the company confirmed that no on-market purchases or sales were conducted for price stabilization and that it continues to meet Hong Kong’s minimum public float requirements, underscoring regulatory compliance following the completion of post-listing stabilization activities.
More about InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange under stock code 3696. While the announcement does not detail its business operations, it confirms the company is participating in Hong Kong’s capital markets through a global equity offering, targeting both international and Hong Kong investors.
Average Trading Volume: 6,403,340
Current Market Cap: HK$29.57B
Find detailed analytics on 3696 stock on TipRanks’ Stock Analysis page.